| Name | tasimelteon |
|---|---|
| Synonyms |
Hetlioz
Tasimelteon MA 1 N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl]propanamide UNII-SHS4PU80D9 Propanamide, N-[[(1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]- N-{[(1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide VEC-162 |
| Description | Tasimelteon is a melatonin MT1 and MT2 receptor agonist.Target: melatonin receptorTasimelteon is a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) approved by either the FDA or the European Medicines Agency (EMA). Tasimelteon is a potent and specific melatonin (MT1 and MT2) receptor agonist with 2 - 4 times greater affinity for the MT2 receptor. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 442.6±24.0 °C at 760 mmHg |
| Melting Point | 78°C(lit.) |
| Molecular Formula | C15H19NO2 |
| Molecular Weight | 245.317 |
| Flash Point | 221.4±22.9 °C |
| Exact Mass | 245.141586 |
| PSA | 38.33000 |
| LogP | 1.75 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.564 |
| Storage condition | 2-8°C |